Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis-Reference-Cited by-同舟云学术

Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis

Published:2012-12-20 Issue:3 Volume:155 Page:429-435
ISSN:0001-6268
Container-title:Acta Neurochirurgica
language:en
Short-container-title:Acta Neurochir

Author:

Gutenberg A.,Bock H. C.,Reifenberger G.,Brück W.,Giese A.

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s00701-012-1583-y.pdf

Reference22 articles.

1. Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR (2012) Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. J Neurooncol 107:395–405

2. Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN (2009) Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys 75:212–219

3. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, Loeffler JS (2006) Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 12:4738–4746

4. Chalmers AJ, Ruff EM, Martindale C, Lovegrove N, Short SC (2009) Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Int J Radiat Oncol Biol Phys 75:1511–1519

5. De Sanctis V, Mazzarella G, Osti MF, Valeriani M, Alfo M, Salvati M, Banelli E, Tombolini V, Enrici RM (2006) Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. Anticanc Drugs 17:969–975

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide;Cochrane Database of Systematic Reviews;2021-03-12

2. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas;PLOS ONE;2020-09-03

3. Clinical outcome of patients with glioblastoma multiforme: Single center experience;Journal of Oncological Sciences;2017-12

4. Is the prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis;Cancer Management and Research;2017-09

5. Therapeutic innovations in endocrine diseases – part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas;La Presse Médicale;2016-06